France-based biopharmaceutical firm Genfit S.A. has made significant strides in the development of drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's flagship product, Elafibranor, is currently undergoing Phase III clinical trials to target primary biliary cholangitis patients. Additionally, the company is engaged in the development of innovative technologies like NIS4, designed to diagnose nonalcoholic steatohepatitis (NASH) and fibrosis, as well as VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD). Genfit S.A. has advanced its GNS561 drug candidate to Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA), while also conducting Phase 1 trials on both VS-01-ACLF and Nitazoxanide (NTZ) for the treatment of acute-on-chronic liver failure. The company's VS-02-HE is currently undergoing preclinical trials for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia. In addition to its extensive research activities, the company has also signed a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test. Genfit S.A. has also collaborated with Genoscience Pharma to develop and commercialize GNS561 investigational treatment for CCA. Since its inception in 1999, Genfit S.A has remained committed to pursuing innovative and impactful solutions for the prevention and treatment of liver diseases. The company is headquartered in Loos, France.
GENFIT S.A.'s ticker is GNFT
The company's shares trade on the NASDAQ stock exchange
They are based in Loos, France
There are 51-200 employees working at GENFIT S.A.
It is https://www.genfit.com/
GENFIT S.A. is in the Healthcare sector
GENFIT S.A. is in the Biotechnology industry
The following five companies are GENFIT S.A.'s industry peers: